导师资格：博士生导师

所在教研室/单位： 药理学教研室

E-mail：[email protected]

通信地址： 广州市越秀区中山二路74号中山大学北校区科技楼9楼西侧934

办公电话：020-87333258

研究方向：溶瘤病毒疗法（Oncolytic Virotherapy）是一种靶向治疗、免疫治疗和基因治疗相结合的新兴抗肿瘤疗法。本团队专注于新型溶瘤病毒的药物药理研究，研究方向主要包括：1. 溶瘤病毒靶向杀伤肿瘤的分子机制研究；2. 免疫系统对溶瘤病毒的“双刃剑”调控机制研究；3. 应用人工智能和合成生物学策略发展新一代溶瘤病毒。

国家高层次青年人才计划入选者

广东省青年珠江学者

中山大学逸仙学者计划“新锐学者”

个人简历

2024至今，教授，博彩公司排名 ，中山大学
2018-2024，副教授，博彩公司排名 ，中山大学
2015-2018：博士后，中山大学
2010-2015：博士，药理学专业，中山大学
2006-2010：本科，生物技术专业，中山大学

研究方向

溶瘤病毒疗法（Oncolytic Virotherapy）是一种靶向治疗、免疫治疗和基因治疗相结合的新兴抗肿瘤疗法。本团队专注于新型溶瘤病毒的药物药理研究，研究方向主要包括：

  1. 溶瘤病毒靶向杀伤肿瘤的分子机制研究；
  2. 免疫系统对溶瘤病毒的“双刃剑”调控机制研究；
  3. 应用人工智能和合成生物学策略发展新一代溶瘤病毒。

学术成果

  1. 发现了一种新的溶瘤病毒——甲病毒M1；
  2. 解析了溶瘤病毒M1靶向杀伤肿瘤的分子机制；
  3. 基于分子机制定向筛选了溶瘤病毒M1的一系列增效剂。

以上基础研究推动原创新药溶瘤病毒M1在中国和日本进入临床试验阶段。

学术论著

  1. Tan, Jingyi#; Zhang, Jiayu#; Hu, Cheng#; Wang Gongwei; Ren, Qianyao; Wang, Chaoqun; Zeng, Zexin; Hu, Jun; Zhu, Wenbo; Liang, Jiankai; Cai, Jing; Yan, Guangmei; Lin, Yuan*. 2024-Pharmacokinetic enhancement of oncolytic virus M1 by inhibiting JAK‒STAT pathway. Acta Pharmaceutica Sinica B. 2024, 14(6):2554e2566.

  2. Guo, Li#; Hu, Cheng#; Liu, Yang; Chen, Xiaoyu; Song, Deli; Shen, Runling; Liu, Zhanzhen; Jia, Xudong; Zhang, Qinfen; Gao, Yuanzhu; Deng, Zhezhi; Zuo, Tao; Hu, Jun; Zhu, Wenbo; Cai, Jing; Yan, Guangmei; Liang Jiankai*; Lin Yuan*. Directed natural evolution generates a next-generation oncolytic virus with a high potency and safety profile.Nature Communications. 2023, 14(1):3410.

  3. Dan, Jia#; Cai, Jing#; Zhong, Yingqian; Wang, Chaoqun; Huang, Shanyu; Zeng, Ying; Fan, Zhen; Xu, Cuiying; Hu, Linyi; Zhang, Jiayu; Hu, Jun; Liu, Ying; Su, Xingwen; Zhu, Wenbo; Yan, Guangmei; Liang, Jiankai*; Lin, Yuan*. Oncolytic virus M1 functions as a bi-functional checkpoint inhibitor to enhance the antitumor activity of DC vaccine. Cell Reports Medicine. 2023, 4(10):101229.

  4. Song, Deli#; Jia, Xudong#; Gao, Yuanzhu#; Xiao, Tong; Dan, Jia; Shen, Runling; Cai, Jing; Liang, Jiankai; Zhu Wenbo; Hu Jun; Yan Guangmei; Zhang Qinfen*; Lin, Yuan *. STT3A-mediated viral N-glycosylation underlies the tumor selectivity of oncolytic virus M1. Oncogene. 2023, 42(48):3575-3588..

  5. Song, Deli#; Jia, Xudong #; Liu, Xincheng #; Hu, Linyi #; Lin, Kaiying; Xiao, Tong; Qiao, Yangyang; Zhang, Jiayu; Dan, Jia; Wong, Chunwa; Hu, Cheng; Sai, Ke; Gong, Shoufang; Sander, Max; Shen, Runling; Chen, Xiaoyu; Xiao, Xiaoting; Chen, Jiehong; Zhang, Yanming; Wei, Cailv; Xiao, Xiao; Liang, Jiankai; Zhang, Qinfen; Hu, Jun; Zhu, Wenbo; Yan, Guangmei; Lin, Yuan*; Cai, Jing*. Identification of the receptor of oncolytic virus M1 as a therapeutic predictor for multiple solid tumors. Signal Transduction and Targeted Therapy. 2022, 7(1):100.

  6. Liu, Yang#; Xu, Cuiying; Xiao, Xiaoting; Chen, Yinting; Wang, Xiaobo; Liu, Wenfeng; Tan, Yaqian; Zhu, Wenbo; Hu, Jun; Liang, Jiankai; Yan, Guangmei; Lin, Yuan*; Cai, Jing*. Overcoming resistance to oncolytic virus M1 by targeting PI3K-γ in tumor-associated myeloid cells. Molecular Therapy. 2022, 30(12):3677-3693.

  7. Zhu, Wenbo#; Liang, Jiankai; Tan, Jingyi; Guo, Li; Cai, Jing; Hu, Jun; Yan, Guangmei; Liu, Yang; Zhang, Jiayu; Song, Deli; Dan, Jia; Wong, Chun-Wa; Su, Xingwen; Qiu, Pengxin; Lin, Yuan*. Real-Time Visualization and Quantification of Oncolytic M1 Virus In Vitro and In Vivo. Human Gene Therapy. 2021, 32(3-4):158-165.

  8. Zeng, Jiayi; Li, Xiangxue; Sander, Max; Zhang, Haipeng; Yan, Guangmei; Lin, Yuan*. Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas. Frontiers in Immunology. 2021, 12: 721830.

  9. Li, Kai#; Hu, Cheng#; Xing, Fan#; Gao, Mingshi; Liang, Jiankai; Xiao, Xiao; Cai, Jing; Tan, Yaqian; Hu, Jun; Zhu, Wenbo; Yin, Wei; Li, Yuan; Chen, Wenli; Lu, Bingzheng; Mai, Jialuo; Qiu, Pengxin; Su, Xingwen; Yan, Guangmei; Zhang, Haipeng*; Lin, Yuan*. Deficiency of the IRE1α-autophagy axis enhances the antitumor effects of the oncolytic virus M1. Journal of Virology, 2018, 92:e01331-17.

  10. Liang, Jiankai#; Guo, Li#; Li, Kai; Xiao, Xiao; Zhu, Wenbo; Zheng, Xiaoke; Hu, Jun; Zhang, Haipeng; Cai, Jing; Yu, Yaya; Tan, Yaqian; Li, Chuntao; Liu, Xincheng; Hu, Cheng; Liu, Ying; Qiu, Pengxin; Su, Xingwen; He, Songmin; Lin, Yuan*; Yan, Guangmei*. Inhibition of the Mevalonate pathway enhances cancer cell oncolysis mediated by M1 Virus. Nature Communications, 2018, 9: 1524.

  11. Xiao, Xiao#; Liang, Jiankai#; Huang, Chunlong; Li, Kai; Xing, Fan; Zhu, Wenbo; Lin, Ziqing; Xu, Wencang; Wu, Guangen; Zhang, Jifu; Lin, Xi; Tan, Yaqian; Cai, Jing; Hu, Jun; Chen, Xueqin; Huang, Youwei; Qin, Zixi; Qiu, Pengxin; Su, Xingwen; Chen, Lijun; Lin, Yuan*; Zhang, Haipeng*; Yan, Guangmei*. DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage. Nature Communications, 2018, 9: 4342.

  12. Tan, Yaqian#; Lin, Yuan#; Li, Kai; Xiao, Xiao; Liang, Jiankai; Cai, Jing; Guo, Li; Li, Chuntao; Zhu, Wenbo; Xing, Fan; Mai, Jialuo; Gu, Jiayu; Tan, Xiaohong; Yin, Wei; Lu, Bingzheng; Qiu, Pengxin; Su, Xingwen; Gao, Mingshi; Hu, Jun; He, Songmin; Lu, Ling; Gong, Shoufang; Yan, Guangmei; Zhang, Haipeng*. Selective antagonism of Bcl-xL potentiates M1 oncolysis by enhancing mitochondrial apoptosis. Human Gene Therapy. 2018, 29:950-961.

  13. Zhang, Haipeng#; Li, Kai#; Lin, Yuan#; Xing, Fan; Xiao, Xiao; Cai, Jing; Zhu, Wenbo; Liang, Jiankai; Tan, Yaqian; Fu, Liwu; Wang, Fang; Yin, Wei; Lu, Bingzheng; Qiu, Pengxin; Su, Xingwen; Gong, Shoufang; Bai, Xuetao; Hu, Jun*; Yan, Guangmei*. Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma. Science Translational Medicine. 2017, 9:eaam7996.

  14. Cai, Jing#; Lin, Yuan#; Zhang, Haipeng; Liang, Jiankai; Tan, Yaqian; Cavenee, Webster K.*; Yan, Guangmei*. Selective replication of oncolytic virus M1 results in a bystander killing effect that is potentiated by Smac mimetics. Proceedings of the National Academy of Sciences of the United States of America. 2017, 114:6812-6817.

  15. Zhang, Haipeng#; Lin, Yuan#; Li, Kai; Liang, Jiankai; Xiao, Xiao; Cai, Jing; Tan, Yaqian; Xing, Fan; Mai, Jialuo; Li, Yuan; Chen, Wenli; Sheng, Longxiang; Gu, Jiayu; Zhu, Wenbo; Yin, Wei; Qiu, Pengxin; Su, Xingwen; Lu, Bingzheng; Tian, Xuyan; Liu, Jinhui; Lu, Wanjun; Dou, Yunling; Huang, Yijun; Hu, Bing; Kang, Zhuang; Gao, Guangping; Mao, Zixu; Cheng, Shi-Yuan; Lu, Ling; Bai, Xue-Tao; Gong, Shoufang; Yan, Guangmei; Hu, Jun*. Naturally existing oncolytic virus M1 is nonpathogenic for the nonhuman primates after multiple rounds of repeated intravenous injections. Human Gene Therapy. 2016, 27:700-711.

  16. Lin, Yuan#; Zhang, Haipeng#; Liang, Jiankai#; Li, Kai; Zhu, Wenbo; Fu, Liwu; Wang, Fang; Zheng, Xiaoke; Shi, Huijuan; Wu, Sihan; Xiao, Xiao; Chen, Lijun; Tang, Lipeng; Yan, Min; Yang, Xiaoxiao; Tan, Yaqian; Qiu, Pengxin; Huang, Yijun; Yin, Wei; Su, Xinwen; Hu, Haiyan; Hu, Jun*; Yan, Guangmei*. Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers. Proceedings of the National Academy of Sciences of the United States of America. 2014, 111:E4504-4512.

  17. Wu, Sihan#; Lin, Yuan#; Xu, Dong; Chen Jingkao; Shu, Minfeng; Zhou, Yuxi; Zhu, Wenbo; Su, Xingwen; Zhou, Yuehan; Qiu, Pengxin; Yan, Gguangmei*. MiR-135a functions as a selective killer of malignant glioma. Oncogene, 2012, 31:3866-3874.

主持项目

  1. 国家重点研发计划青年科学家项目（合成生物学专项），2021/12-2026/11，500万；
  2. 国家自然科学基金面上项目，2025/01-2028/12，48万；
  3. 国家自然科学基金面上项目，2022/01-2025/12，55万；
  4. 国家自然科学基金面上项目，2020/01-2023/12，54万；
  5. 国家自然科学基金青年科学基金项目，2017/01-2019/12，19万；
  6. 广东省自然科学基金面上项目，2019/10-2022/09，10万；
  7. 广东省自然科学基金博士启动项目，2016/06-2019/06，10万；
  8. 中国博士后科学基金面上资助，2016/01-2018/12，8万；
  9. 中央高校基本科研业务费中山大学青年教师培育项目，2019/01-2021/12，20万；
  10. 中央高校基本科研业务费中山大学青年拔尖科研人才培育项目，2022/01-2024/12，40万；
  11. 博彩公司排名-博彩公司评级 -附属第一医院先进医学技术研究中心项目，2021/12-2024/11，300万。

学术兼职

  1. 中国药理学会教学与科普专业委员会青年委员
  2. 广东省免疫学会青年工作委员会委员
  3. 广东省精准医学应用学会疾病模型分会委员